Krystal Biotech, Inc. KRYS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $389.13M+33.9% | $290.51M+473% | $50.7M— | —— | ||
| $58.05M+8.3% | $53.58M+15.4% | $46.43M+9.4% | $42.46M+52.3% | ||
| $146.83M+29.2% | $113.64M+15.6% | $98.29M— | —— | ||
| $227.93M+1.4% | $224.79M+40.2% | $160.32M+10.4% | $145.2M+113% | ||
| $161.2M+145% | $65.73M+158% | -$112.86M+22.3% | -$145.2M-113% | ||
| 41.4%+18.8pp | 22.6%+245pp | -222.6%— | —— | ||
| $28.27M-4.6% | $29.63M— | —— | $0-100% | ||
| $189.47M+98.7% | $95.36M— | —— | -$139.98M-101% | ||
| -$15.36M-348% | $6.2M+215% | $1.97M— | $0— | ||
| $204.83M+130% | $89.16M+716% | $10.93M+108% | -$139.98M-101% | ||
| 52.6%+21.9pp | 30.7%+9.1pp | 21.6%— | —— | ||
| $6.85+128% | $3.00+3,233% | $0.09+102% | -$5.51-76.0% | ||
| $166.88M+133% | $71.62M+166% | -$108.77M+22.9% | -$141.14M-115% | ||
| 42.9%+18.2pp | 24.7%+239pp | -214.5%— | —— | ||
| $161.2M+145% | $65.73M+158% | -$112.86M+22.3% | -$145.2M-113% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Krystal Biotech, Inc.'s revenue?
- Krystal Biotech, Inc. (KRYS) generated $417.3M in revenue over the trailing twelve months, up 25.1% year over year.
- Is Krystal Biotech, Inc. profitable?
- Krystal Biotech, Inc. reported $225.0M in net income over the trailing twelve months, a 53.9% net margin.
- What is Krystal Biotech, Inc.'s earnings per share?
- Krystal Biotech, Inc.'s diluted EPS over the trailing twelve months is $7.48.
- Where does Krystal Biotech, Inc.'s income statement data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
